 |
14 Diseases |  |
2 Trials |
|
2 Trials |  |
176 News |  |
| «1234 |
- 177Lu-DOTA-girentuximab (TLX250) / Telix
Trial completion, Metastases: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=14, Completed, Sponsor: Radboud University
Recruiting --> Completed
- New P1 trial: Intraoperative Dual-modality Imaging in Renal Cell Carcinoma (clinicaltrials.gov) - Jul 14, 2015
P1, N=22, Recruiting, Sponsor: Radboud University
- Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Metastases: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=25, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Recruiting --> Completed Trial primary completion date: Apr 2015 --> Apr 2016
- New trial: Follow up After Cryoablation of Small Renal Masses. (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=12, Recruiting, Sponsor: Radboud University
- ||||| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Trial initiation date: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT (clinicaltrials.gov) - Dec 10, 2014
P3, N=350, Not yet recruiting, Sponsor: Wilex
Trial primary completion date: Apr 2015 --> Apr 2016 Initiation date: Oct 2014 --> Jun 2015
- | Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=48, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Oct 2014 --> Jun 2015 Active, not recruiting --> Completed
- ||||| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Trial initiation date: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT (clinicaltrials.gov) - Dec 16, 2013
P3, N=350, Not yet recruiting, Sponsor: Wilex
Active, not recruiting --> Completed Initiation date: Jul 2013 --> Oct 2014
- 177Lu-DOTA-girentuximab (TLX250) / Telix
New P2 trial, Metastases: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer (clinicaltrials.gov) - Dec 3, 2013
P2, N=14, Recruiting, Sponsor: Radboud University
- 177Lu-DOTA-girentuximab (TLX250) / Telix
Enrollment open, Metastases: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer (clinicaltrials.gov) - Nov 28, 2013
P2, N=14, Recruiting, Sponsor: Radboud University
Initiation date: Jul 2013 --> Oct 2014 Not yet recruiting --> Recruiting
- Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Avastin (bevacizumab) / Roche
Trial completion, IO biomarker: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 (clinicaltrials.gov) - Nov 28, 2013
P=N/A, N=26, Completed, Sponsor: Radboud University
Not yet recruiting --> Recruiting Recruiting --> Completed
- 177Lu-DOTA-girentuximab (TLX250) / Telix
Trial completion, Metastases: Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer (clinicaltrials.gov) - Jul 17, 2013
P1/2, N=27, Completed, Sponsor: Ludwig Institute for Cancer Research
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Trial completion, Surgery, Metastases: Monoclonal Antibody Therapy (Rencarex (clinicaltrials.gov) - May 20, 2013
P3, N=864, Completed, Sponsor: Wilex
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 177Lu-DOTA-girentuximab (TLX250) / Telix
Enrollment change, Metastases: Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=27, Completed, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Completed N=18 --> 27
- Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Sutent (sunitinib) / Pfizer
Trial termination, Metastases: Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=6, Terminated, Sponsor: Ludwig Institute for Cancer Research
N=18 --> 27 Active, not recruiting --> Terminated; Closed prematurely due to toxicity
- Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=6, Terminated, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Terminated; Closed prematurely due to toxicity N=14 --> 6
- |||||||||| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
New P3 trial: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT (clinicaltrials.gov) - Jan 3, 2013
P3, N=350, Not yet recruiting, Sponsor: Wilex
- Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
New trial, Metastases: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center